News and views from the Etcembly team

All Posts

Dec 10, 20241 min read

Advancing Protein Docking with DoRIAT

Docking Run Interpretation and Annotation Tool (DoRIAT) emerges as a standout innovation

Oct 31, 20241 min read

Etcembly are finalists in the Fierce Innovation Awards

We are delighted that our generative AI platform EMLy™️ has been shortlisted as a finalist in the Fierce Innovation Awards 2024

Oct 16, 20242 min read

Etcembly and University of Surrey launch pioneering study to unlock next-generation cancer treatments from survivors

British techbio innovator Etcembly is teaming up with researchers and clinicians from the University of Surrey to launch a groundbreaking...

Oct 2, 20242 min read

Etcembly launches groundbreaking research study searching for cancer cures in survivors

British techbio innovator Etcembly has launched a groundbreaking new research study aiming to uncover new targets for cancer therapies

Aug 22, 20241 min read

Etcembly have been picked by Oliver Sims of Octopus Ventures as one of the top 13 techbio companies to watch.

Read the full story about top techbio companies here:

Aug 11, 20241 min read

Etcembly launching groundbreaking study to uncover whether cancer survivors hold the key to new cures

Dec 2, 20231 min read

Could AI cure cancer?

Marc Emmer at Inc. highlights how our approach could accelerate the development of new immunotherapies. https://www.inc.com/marc-emmer/c...

Dec 2, 20231 min read

Etcembly featured in BIA TechBio 2023 report

Etcembly are showcased as one of the companies driving the UK's AI revolution.

Dec 2, 20231 min read

Interview with CEO Michelle Teng in Inside Precision Medicine

Etcembly co-founder Michelle Teng talks to Helen Albert about her journey in science

Dec 2, 20231 min read

Supporting the next generation in biotech

Discover how we're enabling our former intern Gusztav Milotay to pursue a PhD at the University of Oxford. https://www.harwellcampus.com/...

Dec 2, 20231 min read

Etcembly aims at cancer with AI-driven, rapid TCR engineering technology

Caroline Richards, BioWorld explores how our AI-driven approach is enabling TCR discovery and optimisation at unprecedented scale and speed

Sep 19, 20231 min read

Etcembly's TCR therapeutics featured in Forbes

AI expert and futurist Bernard Marr has written about Etcembly's innovative AI approach to developing TCR-based cancer therapeutics

Aug 22, 20231 min read

Etcembly's T-cell engager featured in Inside Precision Medicine

The announcment of Etcembly's picomolar affinity bispecific T-cell engager targeting PRAME, ETC-101, covered by inside Precision Medicine

Aug 22, 20232 min read

Etcembly reveals world’s first generative AI-designed T cell engager with picomolar affinity

Techbio innovator Etcembly reveals world’s first generative AI-designed bispecific T cell engager with picomolar affinity.

Dec 14, 20223 min read

Etcembly announces breakthrough in optimising TCR assets

Etcembly Announces Breakthrough in Optimising TCR Assets. Successful Financing Brings in Singapore VC iGlobe Partners.

Mar 15, 20222 min read

Etcembly Appoints Scott Cuthill as Chief Business Officer

Etcembly Appoints Scott Cuthill as Chief Business Officer. The Oxford based company is transforming TCR immunotherapy research.

Feb 7, 20221 min read

Research Complex at Harwell welcomes Etcembly

Research Complex at Harwell is delighted to welcome Etcembly.

Feb 7, 20223 min read

Etcembly establishes new lab & office space at Oxford Science Park

Immune-focused machine learning firm joins leading AI cohort on Park

Feb 7, 20222 min read

Zelluna Immunotherapy AS Announces Exclusive Research Collaboration with Etcembly Limited

Zelluna Immunotherapy AS announces an exclusive research collaboration with Etcembly Ltd to discover...

Feb 7, 20222 min read

Oxford-based machine learning start-up Etcembly secures Private Seed Funding

Founders, Michelle Teng and Jacob Hurst, bring a unique blend of machine learning and immunology expertise to a next generation biotech